Mr. Squibbs | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Mr. Squibbs

Sort by

Viewing results 1‒25 of 328

Biotech
Investors hunt for biotech bargains as market shows signs of a thaw
...“We were looking at the outlook and it was quite clear what was coming, way before Mr Putin decided to invade Ukraine, which obviously made the whole thing a lot worse,” he said....
October 26, 2022
Berkshire Hathaway Inc
Berkshire reveals confidential bets on Verizon and Chevron
...It increased its stakes in AbbVie, Bristol-Myers Squibb and Merck, but sold out of Pfizer....
February 17, 2021
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
Berkshire Hathaway Inc
Buffett pulls back on banks and bets on drugmakers
...Mr Buffett did not respond to a request for comment....
November 17, 2020
Special ReportFT Health: Cell Therapies
Why investors cannot resist immunotherapy
...A new Syncona cell therapy company will be set up shortly, Mr Murphy says, building on research at the University of Edinburgh into macrophages....
September 15, 2020
News in-depthUS Treasury bonds
Vaccine-led rise in bond yields ripples through markets
...Mr Michele argued that the US central bank was unlikely to let Treasury yields rise significantly, given the potential financial damage....
November 10, 2020
FT Health
FT Health: Fighting vaccine nationalism
...Why Doctors Aren’t So Sure Trump Is Feeling Better From Covid-19 Mr Trump’s physician has given an incomplete, upbeat picture of his health....
October 7, 2020
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
News in-depthInvestor activism
SEC disclosure change would allow activists to ‘go dark’, lawyers warn
...But with just under $2.5bn invested in US equities at the end of March 2020, Starboard Value, which has led campaigns against drugmaker Bristol-Myers Squibb and ecommerce giant eBay, would not be required...
July 23, 2020
Celgene Corp
Amgen to buy Celgene’s Otezla in $13.4bn deal
...But Mr Porges said investors are likely to be “sceptical” that its patent protection could last for that long....
August 26, 2019
Gilead Sciences Inc
Gilead buys cancer therapy specialist Forty Seven in $4.9bn deal
...The Forty Seven acquisition is Mr O’Day’s second major deal since taking the helm two years ago....
March 2, 2020
Tesla Inc
Hedge fund Renaissance built stake ahead of Tesla share surge
...Filings with the Securities and Exchange Commission show Renaissance owned almost 4m Tesla shares at the end of last year, making the Elon Musk company its second-largest holding behind Bristol-Myers Squibb...
February 18, 2020
Mergers & Acquisitions
Global dealmaking gets off to sluggish start in 2020
...Mr Philip and others cautioned that it was too soon to draw a conclusion on the year’s activity based on a single month of announced deals....
February 2, 2020
FirstFT
FirstFT: Today’s top stories
...Mr Trump took office — also the lowest level since November....
May 7, 2020
Mergers & Acquisitions
Wall Street M&A fees drop by more than $500m in 2019
...M&A fees for Bank of America rose 16 per cent to $1.3bn, with Mr Ramsey pointing to the bank’s focus on smaller deals for part of its gain....
January 17, 2020
Drug prices
Pfizer and other drugmakers start 2020 with price rises
...In 2016, Mr Trump promised to cut drug costs for patients but he has taken few steps to put his proposals into action....
January 3, 2020
Bristol-Myers Squibb Co
Starboard to vote against Bristol-Myers Squibb’s Celgene deal
...Mr Smith added that the board should evaluate alternatives to bolster BMS’s prospects, including a sale of the company....
February 28, 2019
FT Live
Global Private Banking Awards 2024
Celebrating excellence in wealth management
Thursday, 7 NovemberThe Landmark London, London, UK
Mergers & Acquisitions
Activist targets Bristol-Myers Squibb ahead of Celgene deal
...The firm recently invested $200m in Papa John’s International, the pizza chain, where Mr Smith took over as company chairman....
February 20, 2019
The Top LineTom Braithwaite
Shareholders need to stand up and fight bad M&A
...In Occidental’s case it is not just Mr Icahn who is exercised....
June 28, 2019
News in-depthPharmaceuticals sector
Celgene deal a ‘catalyst’ for pharma takeovers
...Bristol-Myers Squibb’s $90bn takeover of Celgene — which one architect of the deal boasted was such a good fit it was like two Lego bricks coming together — represents one of the biggest acquisitions in...
January 3, 2019
Mergers & Acquisitions
US companies power a surge in megadeals in 2019
...“I think we are going to see a rise in Asian activity,” said Mr Aquila. “While we won’t see many US-China deals, we will see M&A within Asia and between Asia and other parts of the world....
December 31, 2019
On Wall StreetJames Fontanella-Khan
Why old-school asset managers are copying the activists
...The decision by Wellington Management to speak out against Bristol-Myers Squibb’s $90bn takeover of rival drugmaker Celgene has shocked many on Wall Street....
March 8, 2019
News in-depthCompanies
Corporate year in review: deals, drama, spies and successes
...Big Pharma looks to biotechs The biggest deal of the year (so far) came right at the start, with Bristol-Myers Squibb paying $93bn for Celgene....
December 20, 2019
Special ReportRevitalised Cities: Tampa and St Petersburg
Downtown developments raise Tampa’s prospects
...While Mr Nozar admits the real estate market in the US is softening, he says Mr Vinik and Mr Gates are long-term investors and have committed the funds for the project....
September 20, 2019
FirstFT
FirstFT: Today’s top stories
...According to SEC filings, Elon Musk’s company is the $60bn hedge fund’s second largest holding, behind Bristol-Myers Squibb....
February 18, 2020
Mergers & Acquisitions
JPMorgan Chase set to scoop record fee for Allergan sale
...Mr Saunders....
August 13, 2019
Investor activism
‘Barbarian’ investors gain acceptance as useful market force
...In February, Wellington Management, the US fund manager, published a letter warning that it would vote against Bristol-Myers Squibb’s planned acquisition of Celgene for $90bn....
July 5, 2019

Previous pagePage 1 of 14Next page